Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders

Background and Objectives Neuroinflammation contributes to Parkinson disease (PD) pathology, and inflammatory biomarkers may aid in PD diagnosis. Proximity extension assay (PEA) technology is a promising method for multiplex analysis of inflammatory markers. Neuroinflammation also plays a role in related neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and Alzheimer disease (AD). The aim of this work was to assess the value of inflammatory biomarkers in newly diagnosed patients with PD and in patients with DLB and AD. Methods Patients from the Norwegian ParkWest and Dementia Study of Western Norway longitudinal cohorts (PD, n = 120; DLB, n = 15; AD, n = 27) and 44 normal controls were included in this study. A PEA inflammation panel of 92 biomarkers was measured in the CSF. Disease-associated biomarkers were identified using elastic net (EN) analysis. We assessed the discriminatory power of disease-associated biomarkers using receiver operating characteristic (ROC) curve analysis and estimated the optimism-adjusted area under the curve (AUC) using the bootstrapping method. Results EN analysis identified 9 PEA inflammatory biomarkers (ADA, CCL23, CD5, CD8A, CDCP1, FGF-19, IL-18R1, IL-6, and MCP-2) associated with PD. Seven of the 9 biomarkers were included in a diagnostic panel, which was able to discriminate between those with PD and controls (optimism-adjusted AUC 0.82). Our 7-biomarker PD panel was also able to distinguish PD from DLB and from AD. In addition, 4 inflammatory biomarkers were associated with AD and included in a panel, which could distinguish those with AD from controls (optimism-adjusted AUC 0.87). Our 4-biomarker AD panel was also able to distinguish AD from DLB and from PD. Discussion In our exploratory study, we identified a 7-biomarker panel for PD and a 4-biomarker panel for AD. Our findings indicate potential inflammation-related biomarker candidates that could contribute toward PD-specific and AD-specific diagnostic panels, which should be further explored in other larger cohorts.

[1]  B. Mollenhauer,et al.  Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Tansey,et al.  Inflammation and immune dysfunction in Parkinson disease , 2022, Nature Reviews Immunology.

[3]  S. Hasselbalch,et al.  Elevated CSF inflammatory markers in patients with idiopathic normal pressure hydrocephalus do not promote NKCC1 hyperactivity in rat choroid plexus , 2021, Fluids and Barriers of the CNS.

[4]  K. Blennow,et al.  Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics , 2021, Cells.

[5]  V. Mok,et al.  Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  K. Kultima,et al.  Different Inflammatory Signatures in Alzheimer’s Disease and Frontotemporal Dementia Cerebrospinal Fluid , 2021, Journal of Alzheimer's disease : JAD.

[7]  A. Peters,et al.  Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of population-based cohort studies , 2021, medRxiv.

[8]  M. Vila,et al.  CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease. , 2020, Brain : a journal of neurology.

[9]  L. Fugger,et al.  Inflammation-related plasma and CSF biomarkers for multiple sclerosis , 2020, Proceedings of the National Academy of Sciences.

[10]  O. Hansson,et al.  Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease , 2019, Acta Neuropathologica Communications.

[11]  B. Bloem,et al.  Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms , 2019, BMC neurology.

[12]  P. Svenningsson,et al.  Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson’s Disease , 2019, Journal of Parkinson's disease.

[13]  H. Gürvit,et al.  Neuroinflammation Mediators are Reduced in Sera of Parkinson's Disease Patients with Mild Cognitive Impairment. , 2019, Noro psikiyatri arsivi.

[14]  P. Udagama,et al.  Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study , 2019, BMC Neurology.

[15]  J. Rowe,et al.  Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  S. Friis,et al.  Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes , 2018, Journal of Neuroinflammation.

[17]  Yong Cheng,et al.  Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis , 2018, Front. Immunol..

[18]  Y. Surova,et al.  Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders , 2018, Alzheimer's & Dementia.

[19]  D. Aarsland,et al.  A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer’s Disease , 2018, Front. Neurol..

[20]  Alan J. Thomas,et al.  Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  S. Zheng,et al.  Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms , 2016, Front. Immunol..

[22]  K. Lange,et al.  Next Generation Statistical Genetics: Modeling, Penalization, and Optimization in High-Dimensional Data. , 2014, Annual review of statistics and its application.

[23]  Sara Hall,et al.  Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.

[24]  H. Hakonarson,et al.  Large sample size, wide variant spectrum, and advanced machine-learning technique boost risk prediction for inflammatory bowel disease. , 2013, American journal of human genetics.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[26]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[27]  Sanford Weisberg,et al.  An R Companion to Applied Regression , 2010 .

[28]  K. Blennow,et al.  CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[30]  D. Aarsland,et al.  Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[31]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[32]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[33]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[34]  C. Morris,et al.  Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease , 2000, Neuroscience Letters.

[35]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[36]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[37]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[38]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[39]  L. Varga.  Bootstrap methods and their applications , 2022 .